Psychiatric medications are a crucial part of treatment for many mental health conditions, helping to ease symptoms and boost mental well-being. But there are some more commonly prescribed.

Mental health conditions are complex. Just one medication will help in some cases. Other times, you might try a few different medications before finding the right one or even need more than one medication.

Psychiatric medications are an important part of many people’s treatment plans, including therapy and other strategies. While they can’t cure your mental health condition, they can help manage your symptoms.

Eoin Treacy's view

The pharmaceutical industry thrives on chronic conditions. That’s why some of the most successful companies cater to diabetes or why Viagra was such a big hit. The pandemic has seen an explosion in the number of people seeking mental health solutions. It is now much more socially acceptable to talk about mental health and to a certain extent is faddish on social media. That suggests a growth market. I took the list of medications in the above article and traced down the parent companies.

Pfizer – Zoloft (depression), Xanax patent (anxiety, panic disorders) The company was the winner of the pandemic vaccine race but the share is now suffering as most people feel no need to volunteer for booster shots.
Forest Labs – Lexapro (depression), Celexa (depression)

GlaxoSmithKline – Wellbutrin (depression), Paxil (OCD) The share has been ranging for nearly twenty years.

Shire – Adderall (ADHD), Vyvanse (ADHD) The company was taken over my Takeda Pharmaceutical. That share continues to trend higher.

Eli Lilly - Prozac (depression) (1986), Zyprexa (antipsychotic), Duloxetine (depression, stress, urinary incontinence) The share continues to trend higher in a consistent manner.

Viatris – Effexor (depression) The share remains in a consistent medium-term downtrend which is sign of trouble on the balance sheet.

Roche – Klonopin (seizures), Vallum (alcohol withdrawal) The share continues to unwind the overextension relative to the 200-day MA.

Astra Zeneca – Seroquel (anxiety) The share continues to trend higher in a consistent manner but is short-term overbought.

Sanofi – Kadvay (ADHD) The share is short-term overbought as it attempts to breakout of an eight-year range.

Merck – Elavil (depression) The share is still in a consistent uptrend.
Otsuka Pharmaceuticals – Abilify (ADHD, bipolar). The company is unlisted.

Organon – Remeron (depression) The share has steadied of late but a medium-term downtrend is still in place.  

Novartis – Focailin (ADHD). The share is just breaking out of a medium-term range within a much lengthier period of consolidation. 

Many of these shares are short-term overbought and would be best accumulated on weakness.